Sep 7, 2021 4:30 pm EDT iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
Aug 25, 2021 7:30 am EDT iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
Jul 15, 2021 5:10 pm EDT iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
Jul 8, 2021 4:15 pm EDT iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
Jun 9, 2021 4:30 pm EDT iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink
May 17, 2021 7:00 am EDT iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021 8:15 am EDT iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021
May 6, 2021 4:15 pm EDT iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program